Treatment of severe beta-thalassemia (patients) with myleran.
We previously reported that myleran, a cell cycle nonspecific drug, can stimulate gamma-globin gene expression in anemic adult rhesus monkeys. This finding prompted us to treat two patients with severe beta-thalassemia with myleran. Both patients received an initial course of therapy, constantly of myleran at a dosage of 0.2 mg/kg/d for 9 days followed by 0.15 mg/kg/d for the next 11 days. One patient received an additional 20-day course of myleran at a dosage of 0.2 mg/kg/d beginning 44 days after completion of the first course. No severe ill effects related to the drug were observed during or after drug administration. After 20 days of myleran treatment, levels of HbF and reticulocytes increased in both patients and level of F cells increased in patient 1. In patient 1, Hb concentration rose from 42g/L (9 days after transfusion) before treatment to a maximum of 65g/L afterward; in patient 2, it rose from 74g/L to a maximum of 106g/L. A value of 15g/L above baseline lasted for about 5 months in both patients. Hypomethylation of bone marrow DNA near the gamma-globin gene was demonstrated in patient 1.
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
D P
DP
Liu
C C
CC
Liang
Z H
ZH
Ao
P C
PC
Jia
S S
SS
Chen
R X
RX
Wang
L J
LJ
Liu
H Q
HQ
Jin
D Y
DY
Zha
Y W
YW
Huang
D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D004247:DNA / Q000378:metabolism; D004906:Erythrocyte Count; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis; D005914:Globins / Q000235:genetics; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008745:Methylation; D012854:Sister Chromatid Exchange; D013789:Thalassemia / Q000188:drug therapy*; D013997:Time Factors
D005914:Globins; D004247:DNA; D005319:Fetal Hemoglobin; D002066:Busulfan